AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.
Key Points
The drug could eventually generate more than $1 billion annually.
Once-daily dosing could help the drug gain patient adoption.
AbbVie’s neuroscience portfolio continues to generate strong sales growth.
- 10 stocks we like better than AbbVie ›
Earlier this week, the U.S. Food and Drug Administration (FDA) approved AbbVie's (NYSE: ABBV) Juvmo (tavapadon). This is a once-daily pill for adults with Parkinson's disease that gives the pharmaceutical giant a new treatment for an ailment affecting more than 10 million people worldwide.
The approval also puts one of the key assets from AbbVie's $8.7 billion acquisition of Cerevel Therapeutics on the market. AbbVie completed that deal in 2024 in an effort to strengthen its neuroscience pipeline, and Juvmo now has a chance to start generating a return on that investment.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
How it works
Juvmo works by selectively activating D1/D5 dopamine receptors in the brain. Dopamine plays an important role in controlling body movement, and Parkinson's progressively destroys the cells that produce it. Now, with Juvmo, AbbVie owns the first FDA-approved Parkinson's treatment to selectively target these particular receptors, giving doctors another option for managing symptoms such as stiffness, tremors, and difficulty moving.
AbbVie is building another major growth business
Neuroscience is already becoming a significant business for AbbVie. Combined sales of Vraylar, Ubrelvy, and Qulipta reached roughly $5.9 billion in 2025, and AbbVie expects its neuroscience portfolio to keep expanding as newer products gain market share. Juvmo could be another contributor to that growth. While near-term revenue from the drug is only expected to reach $8 million this year and $70 million next year, by 2040, Juvmo could deliver $1.4 billion in annual sales.
These aren't trivial numbers as AbbVie continues moving beyond Humira, which once generated more than $20 billion in annual sales before losing U.S. patent exclusivity. To be clear, Juvmo is unlikely to become another Humira on its own, but AbbVie doesn't need it to.
The company is increasingly replacing its dependence on one blockbuster with a collection of growing franchises across neuroscience, immunology, and oncology. Juvmo adds another commercial asset to that strategy while providing some early validation for the $8.7 billion Cerevel acquisition.
Should you buy stock in AbbVie right now?
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $365,910!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,418,530!*
Now, it’s worth noting Stock Advisor’s total average return is 930% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of October 3, 2026.
Jeff Siegel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie. The Motley Fool has a disclosure policy.
Recommended Articles
